首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1626595

全球流式細胞儀市場規模：依產品、技術、應用、最終用戶、區域覆蓋和預測

Global Flow Cytometry Market Size By Product, By Technology, By Application, By End-User, By Geographic Scope And Forecast

出版日期: 2024年11月13日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

流式細胞儀市場規模及預測

2024年流式細胞儀市場規模價值 46.8億美元，預計到2031年將達到 80.6億美元，2024年至2031年的年複合成長率為 7.75%。

流式細胞儀是一種先進的實驗室技術，可以以極高的精確度和速度分析單一細胞。

這項先進的技術利用流式細胞儀。流式細胞儀是一種專門的儀器，可以測量穿過雷射光束的細胞的物理和化學特性。

流式細胞儀每秒可快速分析數千個細胞，實現高效、全面的資料收集。

此技術能夠偵測到細胞特性的細微變化，確保分析的準確性和精確性。

流式細胞儀可以測量多種細胞特徵，包括大小、形狀、粒度和表面標誌表達。

此技術可以同時測量每個細胞的多個參數，全面了解細胞特性。

流式細胞儀徹底改變了細胞生物學，並已成為研究、診斷和藥物開發的重要工具。

全球流式細胞儀市場動態

影響全球流式細胞儀市場的關鍵市場動態是：

主要市場驅動因子

慢性病發生率不斷上升：慢性病的發生率不斷上升，推動了流式細胞儀的需求。該技術在各種疾病的診斷和監測中發揮著重要作用。根據世界衛生組織（WHO）的資料，到2023年，慢性病將佔全球死亡人數的71%。

癌症研究中的應用日益廣泛：流式細胞儀在癌症研究和診斷中的應用迅速擴大。流式細胞儀可以詳細分析腫瘤細胞和免疫反應。這項技術將有助於開發針對性治療方法和監測治療結果。例如，2024年3月15日，Beckman Coulter宣布了專為癌症免疫治療研究設計的新型流式細胞儀平台。

在藥物研發中的應用日益廣泛：製藥公司日益在藥物研發中使用流式細胞儀。該技術對於高通量篩選和先導化合物最佳化非常有用。它們在評估藥物功效和毒性方面也發揮著重要作用。2024年1月，美國FDA報告40%的新藥核准包括流式細胞儀資料。

促進HIV/AIDS監測的進步：流式細胞儀對於診斷和監測HIV/AIDS非常重要。流式細胞儀可以準確測量 CD4+ T 細胞計數，這對於疾病管理非常重要。技術的進步使得這些測試更容易獲得且更便宜。聯合國愛滋病規劃署2023年 12月報告指出，由於流式細胞儀等檢測方法的改進，84%的愛滋病毒感染者了解自己的感染狀況。

主要問題

高成本阻礙了廣泛採用：流式細胞儀設備需要大量的初始投資，這可能會阻礙其在預算有限的小型研究機構和實驗室中的採用。這種經濟障礙可能會限制人們獲得這種寶貴的技術，特別是在發展中地區。

操作複雜性和資料分析挑戰：流式細胞儀的有效操作需要專門的訓練和專業知識。此外，複雜的資料分析和解釋過程需要專門的軟體和生物資訊技能。這些挑戰可能會限制研究人員和臨床醫生使用流式細胞儀的效率和可及性。

影響準確性的技術限制：儘管技術進步，流式細胞儀技術在靈敏度、分辨率和分析稀有細胞群的能力方面仍然存在限制。克服這些技術障礙對於提高流式細胞儀的準確性和可靠性非常重要。

與替代技術的競爭限制了市場成長：流式細胞儀與其他細胞分析技術競爭，例如質譜流式細胞儀和成像流式細胞儀。這些替代技術可能提供某些優勢，例如更高的靈敏度和即時視覺化功能。這樣的競爭可能會限制傳統流式細胞儀的市場成長。

主要趨勢

幹細胞研究的需求不斷成長：不斷擴大的幹細胞研究領域在很大程度上依賴流式細胞儀。流式細胞儀可以精確識別和分離幹細胞群。這項技術對於再生醫學治療的發展非常重要。例如，2024年4月，Thermo Fischer Scientific推出了針對幹細胞分析最佳化的新型流式細胞儀。

在免疫學研究中的用途不斷擴大：流式細胞儀的詳細分析在免疫學研究中變得越來越重要。這對於了解免疫反應和開發免疫療法非常重要。美國國立衛生研究院報告指出，使用流式細胞儀的免疫學研究經費將在 23 財政年度增加 30%。

微生物學中越來越多的應用：流式細胞儀在微生物學和傳染病研究中找到了新的用途。流式細胞儀可以快速檢測和鑑定微生物。這項技術對於食品安全、水質和環境監測非常重要。例如，2024年 2月，BD Biosciences 推出了一種新的流式細胞儀檢測方法，用於快速檢測抗生素抗藥性細菌。

促進血液學診斷的進步：流式細胞儀繼續徹底改變血液學診斷。這項技術對於診斷和監測血液疾病非常重要。美國血液學會於2023年 11月報告指出，目前85%的血液學實驗室使用流式細胞儀作為主要診斷工具。

Rising Prevalence of Chronic Diseases: The increasing incidence of chronic diseases drives demand for flow cytometry. This technology plays a crucial role in diagnosing and monitoring various conditions. According to the World Health Organization, chronic diseases accounted for 71% of global deaths in 2023.

Growing Applications in Cancer Research: Flow cytometry's use in cancer research and diagnostics is expanding rapidly. It enables detailed analysis of tumor cells and immune responses. This technology aids in developing targeted therapies and monitoring treatment efficacy. For instance, in March 15, 2024, Beckman Coulter announced a new flow cytometry platform specifically designed for cancer immunotherapy research.

Increasing Adoption in Drug Discovery: Pharmaceutical companies are increasingly using flow cytometry in drug discovery. The technology helps in high-throughput screening and lead optimization. It also plays a vital role in assessing drug efficacy and toxicity. The U.S. FDA reported in January 2024 that 40% of new drug approvals involved flow cytometry data in their submissions.

Fueling Advancements in HIV/AIDS Monitoring: Flow cytometry remains essential for HIV/AIDS diagnosis and monitoring. It accurately measures CD4+ T-cell counts, crucial for disease management. Technological improvements are making these tests more accessible and affordable. UNAIDS reported in December 2023 that 84% of people living with HIV know their status, largely due to improved testing methods including flow cytometry.

Key Challenges:

High Cost Hindering the Widespread Adoption: The substantial initial investment required for flow cytometry equipment can hinder its adoption by smaller research institutions or laboratories with limited budgets. This financial barrier may restrict access to this valuable technology, particularly in developing regions.

Operational Complexity and Data Analysis Challenges: Operating flow cytometry equipment effectively demands specialized training and expertise. Additionally, the intricate process of data analysis and interpretation necessitates specialized software and bioinformatics skills. These challenges can potentially limit the efficiency and accessibility of flow cytometry for researchers and clinicians.

Technological Limitations Affecting the Accuracy: Despite advancements, flow cytometry technology still faces limitations in terms of sensitivity, resolution, and the ability to analyze rare cell populations. Overcoming these technological hurdles is imperative for enhancing the accuracy and reliability of flow cytometry.

Competition from Alternative Technologies Restricting the Market Growth: Flow cytometry competes with other cell analysis techniques, including mass cytometry and imaging flow cytometry. These alternative technologies may offer certain advantages, such as higher sensitivity or real-time visualization capabilities. Such competition can potentially limit the market growth for traditional flow cytometry.

Key Trends

Rising Demand in Stem Cell Research: The expanding field of stem cell research heavily relies on flow cytometry. It enables precise identification and isolation of stem cell populations. This technology is crucial for developing regenerative medicine therapies. For instance, in April 2024, Thermo Fisher Scientific launched a new flow cytometer specifically optimized for stem cell analysis.

Growing Use in Immunology Studies: Immunology research increasingly depends on flow cytometry for detailed analysis. This is crucial for understanding immune responses and developing immunotherapies. The National Institutes of Health reported a 30% increase in immunology research grants utilizing flow cytometry in fiscal year 2023.

Increasing Applications in Microbiology: Flow cytometry is finding new applications in microbiology and infectious disease research. It enables rapid detection and characterization of microorganisms. This technology is crucial for food safety, water quality, and environmental monitoring. For instance, in February 2024, BD Biosciences introduced a new flow cytometry assay for rapid detection of antibiotic-resistant bacteria.

Fueling Advancements in Hematology Diagnostics: Flow cytometry continues to revolutionize hematology diagnostics. This technology is crucial for diagnosing and monitoring blood disorders. The American Society of Hematology reported in November 2023 that 85% of hematology laboratories now use flow cytometry as a primary diagnostic tool.

Global Flow Cytometry Market Regional Analysis

Here is a more detailed regional analysis of the global flow cytometry market:

North America

North America has established itself as the dominating region in the global flow cytometry market, driven by substantial investments in research and development, advanced healthcare infrastructure, and a high prevalence of chronic diseases.

The region boasts a large number of academic research institutions and pharmaceutical companies that extensively utilize flow cytometry in their studies and drug development processes.

This widespread adoption is further supported by favorable reimbursement policies and government initiatives promoting advanced diagnostic technologies.

According to the National Institutes of Health (NIH), funding for research projects involving flow cytometry increased by 15% in fiscal year 2023 compared to the previous year.

The market leadership of North America is also attributed to the presence of major flow cytometry manufacturers and continuous technological advancements in the field.

These companies are constantly innovating to improve the speed, accuracy, and versatility of flow cytometry instruments and reagents.

The region's strong focus on personalized medicine and immunotherapy research further fuels the demand for advanced flow cytometry solutions.

for instance, in June 1, 2024, Becton, Dickinson and Company (BD) announced the launch of its next-generation flow cytometer, which offers enhanced sensitivity and faster processing times, further solidifying North America's position in the global market.

Asia Pacific

The Asia Pacific region is projected to experience a rapid CAGR growth during the forecast period, driven by increasing healthcare expenditure and rising awareness about advanced diagnostic technologies.

Rapid economic development in countries like China and India is leading to improved healthcare infrastructure and greater adoption of sophisticated medical equipment.

The region's large population base and growing incidence of chronic diseases create a vast potential market for flow cytometry applications.

According to China's National Bureau of Statistics, healthcare spending in the country increased by 12.5% in 2023, reaching 7.8 trillion yuan (approximately $1.2 trillion USD).

Government initiatives to promote biotechnology research and development are further fueling the expansion of the flow cytometry market in Asia Pacific.

Many countries in the region are investing heavily in life sciences research and establishing state-of-the-art research facilities. This trend is attracting global pharmaceutical and biotechnology companies to set up research centers in the region.

For instance, in April 15, 2024, Sysmex Corporation, a leading Japanese flow cytometry manufacturer, announced the opening of a new R&D center in Singapore, focusing on developing novel flow cytometry applications for cancer diagnostics and immunotherapy research.

Global Flow Cytometry Market: Segmentation Analysis

The Global Flow Cytometry Market is segmented based on By Product, By Technology, By Application, By End-User, and Geography.

Flow Cytometry Market, By Product

Instruments
Cell Analyzers
Cell Sorters
Reagents & Consumables
Software
Accessories
Services

Based on Product, the Global Flow Cytometry Market is bifurcated into Instrument, Reagents & Consumables, Software, Accessories, Services. The instrument segment dominating the global flow cytometry market. This is due to increased penetration brought about by advancements in technology. However, the software segment is growing at a rapid CAGR within the global flow cytometry market. Software is essential for controlling and collecting data from cytometers, analysing data, and providing statistical insights.

Flow Cytometry Market, By Technology

Cell-based
Bead-based

Based on Technology, the Global Flow Cytometry Market is bifurcated into Cell-based, Bead-based. The cell-based segment is estimated to dominate the global flow cytometry market during the forecast period. The drug development, cell-based assays are employed to evaluate cell physiological properties and analyze the data gathered. However, the bead-based segment is growing at a rapid CAGR within the global flow cytometry market. These tests, which use sandwich or indirect immunoassay formats, are made especially to measure the number of antibodies present in biological fluids.

Flow Cytometry Market, By Application

Research
Pharmaceutical
Drug Discovery
Stem Cell
In Vitro Toxicity
Apoptosis
Cell Sorting
Cell Cycle Analysis
Immunology
Cell Viability
Others
Industrial
Clinical
Cancer
Organ Transplantation
Immunodeficiency
Hematology
Autoimmune Disorders

Based on Application, the Global Flow Cytometry Market is bifurcated into Research, Industrial, Clinical. The clinical segment is estimated to dominate the global flow cytometry market during the forecast period. It is anticipated that the biotechnology and pharmaceutical industries' growing R&D expenditures will provide a conducive atmosphere for market growth. However, the industrial segment is growing at a rapid CAGR within the global flow cytometry market, because of its growing use in fields including plant tissue culture, tissue culturing, microbiology, and the food sector.

Flow Cytometry Market, By End-User

Commercial Organizations
Biotechnology Companies
Pharmaceutical Companies
CROs
Hospitals
Academic Institutes
Clinical Testing Labs

Based on End-User, the Global Flow Cytometry Market is bifurcated into Commercial Organizations, Hospitals, Academic Institutes, Clinical Testing Labs. The academic institutes segment is dominating the global flow cytometry market. Numerous academic disciplines, including molecular biology, immunology, pathology, plant biology, and marine biology, use the technology. However, the clinical testing labs segment is rapidly growing, because target diseases like cancer are becoming more and more expensive to diagnose.

Flow Cytometry Market, By Geography

North America
Europe
Asia Pacific
Rest of the world

Based on Geography, the Global Flow Cytometry Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North American region has established itself as the dominating region in the global flow cytometry market, driven by substantial investments in research and development, advanced healthcare infrastructure, and a high prevalence of chronic diseases. However, the Asia Pacific region is projected to experience a rapid CAGR growth during the forecast period, driven by increasing healthcare expenditure and rising awareness about advanced diagnostic technologies.

Key Players

The "Global Flow Cytometry Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Siemens Healthcare GmbH, NextStep Solutions, McKesson Corporation, NextGen Healthcare, Genpact Limited, Athena Healthcare, Boston Consulting Group, Change Healthcare, Baker Tilly, USA, LLC, ForeSee Medical, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Flow Cytometry Market Key Developments

In March 2024, the FDA granted Beckman Coulter Life Sciences 510(k) permission to market the DxFLEX Clinical Flow Cytometer in the United States. Thanks to this development, labs may now do high-complexity flow cytometry testing more easily and affordably.
In January 2024, to promote technical innovation and expedite scientific discoveries, Cytek Biosciences, Inc. partnered with Pompeu Fabra University (UPF) and the Centre for Genomic Regulation (CRG). The cooperation opens the door for growth into new applications and highlights the important influence of Cytek's spectral flow cytometry technology.

1 INTRODUCTION OF GLOBAL FLOW CYTOMETRY MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL FLOW CYTOMETRY MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL FLOW CYTOMETRY MARKET, BY TECHNOLOGY

5.1 Overview
5.2 Cell-Based Flow Cytometry
5.3 Bead-Based Flow Cytometry

6 GLOBAL FLOW CYTOMETRY MARKET, BY PRODUCT

6.1 Overview
6.2 Instruments
- 6.2.1 Cell Analyzer
- 6.2.2 Cell Sorter
6.3 Reagents and Consumables
6.4 Services
6.5 Software
6.6 Accessories

7 GLOBAL FLOW CYTOMETRY MARKET, BY APPLICATION

7.1 Overview
7.2 Industrial Applications
7.3 Clinical Applications
- 7.3.1 Cancer
- 7.3.2 Hematology
- 7.3.3 Immunodeficiency Diseases
7.4 Research Applications
- 7.4.1 Pharmaceuticals and Biotechnology
- 7.4.2 Immunology
- 7.4.3 Cell Sorting

8 GLOBAL FLOW CYTOMETRY MARKET, BY END-USER

8.1 Overview
8.2 Hospitals and Diagnostic Laboratories
8.3 Biotechnology and Biopharmaceutical Companies
8.4 Research Laboratories and Institutes

9 GLOBAL FLOW CYTOMETRY MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL FLOW CYTOMETRY MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Biomerieux S.A
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Cytonome St
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Apogee Flow Systems
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Agilent Technologies
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Luminex
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Miltenyi Biotec
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Thermo Fisher Scientific
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Becton
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Dickinson and Company
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Merck KGaA
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments